References
Ell PJ, Gambhir SS. Nuclear medicine in clinical diagnoses and treatment. 3rd ed. New York: Churchill Livingstone; 2004
Hofmann M, Maecke H, Borner R, Weckesser E, Schoffski P, Oei L, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001;28:1751–7
Kowalski J, Henze M, Schuhmacher J, Macke HR, Hofmann M, Haberkorn U. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-DPhe1-Tyr3-octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 2003;5:42–8
Lewington V. Targeted radionuclide therapy for neuroendocrine tumours. Endocr Relat Cancer 2003;10(4):497–501
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Win, Z., Rahman, L., Murrell, J. et al. The possible role of 68Ga-DOTATATE PET in malignant abdominal paraganglioma. Eur J Nucl Med Mol Imaging 33, 506 (2006). https://doi.org/10.1007/s00259-005-0035-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-005-0035-9